Studies microbes and immunity in people with dermatomyositis and lung disease
Compares microbial communities and immune function in people with anti-MDA5 dermatomyositis.
Plain-language title generated from the registry record
Registry title: Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with dermatomyositis who test positive for the anti-MDA5 antibody and who have had a lung wash (bronchoalveolar lavage). Some also have fast-worsening lung disease.
- Age
- 18 to 100 years
- Sex
- All sexes can join.
- Disease stage
- Dermatomyositis with a positive anti-MDA5 antibody. Some people also have rapidly progressive interstitial lung disease (RPILD) and must meet its diagnostic criteria.
- Earlier treatment
- Must have had a bronchoalveolar lavage (a lung wash).
- Biomarker or test result
- Positive anti-MDA5 antibody.
Main reasons for not taking part
- Other connective tissue diseases
- Lung disease caused by infection, tumors, drugs, biochemistry or other factors
- Pregnant or breastfeeding
- Taking part in another clinical trial
- Does not agree to join this study
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06203249, who can take part
Where in China
- PLABeijing, ChinaContact: Zhimei Duan, doctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT06203249
- Record updated
- 12 January 2024
- Original description
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.Read full original descriptionShow less
Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.
Inclusion: Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive; Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD; Must have undergone bronchoalveolar lavage; Age≥18 years old; Patients who signed informed consent forms.
Exclusion: Patients who had other connective tissue diseases; Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors; Pregnant or lactating patients; The patient also participated in any other clinical trial; Disagreement for inclusion in this study.